Archived Releases

February 28, 2019
Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update
Conference Call Scheduled for Friday, March 1 at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on
January 23, 2019
Foamix Announces Appointment of Sharon Barbari to Board of Directors
REHOVOT, Israel , and BRIDGEWATER, N.J. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
November 27, 2018
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Displaying 1 - 10 of 154